• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Authors » Talia Puzantian, PharmD, BCPP

Articles by Talia Puzantian, PharmD, BCPP

Fact Sheet

Risperidone (Risperdal) Fact Sheet [G] for Children and Adolescents

September 23, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Risperidone offers more efficacy and safety data in kids than other antipsychotics and is often used first-line in autistic kids, but you need to expect and monitor for EPS, prolactinemia, and weight gain.


Read More
Fact Sheet

Oxcarbazepine (Oxtellar XR, Trileptal) Fact Sheet [G] for Children and Adolescents

September 23, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Compared to carbamazepine, oxcarbazepine poses less concern for drug interactions and for hepatic or hematologic toxicities; it also does not require serum level monitoring.



Read More
Fact Sheet

Dexmethylphenidate (Azstarys, Focalin, Focalin XR) Fact Sheet [G] for General Psychiatry

September 23, 2023
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Dexmethylphenidate (d-MPH, brand name Focalin) is the D-isomer of methylphenidate and is twice as potent as methylphenidate. 


Read More
Fact Sheet

Nicotine Inhaled (Nicotrol Inhaler) for Children and Adolescents

September 22, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Very high expense and unpleasant side effects make this form of nicotine replacement therapy difficult to recommend as a first-line option since no single therapy has been shown to be more effective than another. 




Read More
Fact Sheet

Nicotine Gum/Lozenge (Nicorette) for Children and Adolescents

September 22, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

First-line intervention for those patients who can stop smoking at initiation of therapy; nicotine in the form of gum or lozenge may act as a substitute oral activity, which may aid in behavior modification.




Read More
Fact Sheet

Naltrexone (ReVia, Vivitrol) for Children and Adolescents

September 22, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Naltrexone, an opioid antagonist, is the first-line medication for alcohol use disorder—though it is also approved for opioid use disorder.




Read More
Fact Sheet

Naloxone (Kloxxado, Narcan Nasal Spray, Zimhi) for Children and Adolescents

September 22, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Opioid replacement therapy via methadone reduces or eliminates illicit use of opioids and criminality associated with opioid use, supporting health and social functioning. 




Read More
Fact Sheet

Methadone (Methadose) for Children and Adolescents

September 22, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Opioid replacement therapy via methadone reduces or eliminates illicit use of opioids and criminality associated with opioid use, supporting health and social functioning. 




Read More
Fact Sheet

Disulfiram (Antabuse) for Children and Adolescents

September 22, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Disulfiram is an aversive treatment, causing a buildup of ethanol’s metabolite acetaldehyde in the serum, which in turn causes symptoms such as flushing, dizziness, nausea, and vomiting.




Read More
Fact Sheet

Buprenorphine/Naloxone (Bunavail, Suboxone, Zubsolv) for Children and Adolescents

September 22, 2023
Joshua Feder, MD, Talia Puzantian, PharmD, BCPP, and Elizabeth Tien, MD

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The combination product is preferred over buprenorphine alone for maintenance because the addition of naloxone affords it a lower potential for injection misuse. 




Read More
Previous 1 2 … 30 31 32 33 34 35 36 37 38 … 43 44 Next
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • RogerSolomon2023.jpg
    General Psychiatry

    EMDR in Practice: A Clinician's Guide to Trauma Reprocessing with Roger Solomon, PhD

    Dr. Roger Solomon provides a comprehensive introduction to Eye Movement Desensitization and Reprocessing (EMDR).

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.